WIRE — Polish pharmaceutical group Polpharma, which has recently acquired the Romanian drug manufacturer Biofarm in a deal valued at about EUR257 million, says that Romania is one of its strategic markets for growth in Central and Eastern Europe and announces it will continue to invest in the Romanian company's development.
"We aggregate wires to encourage regional discovery, sending readers directly back to the original source to explore full coverage."
This is a normalized overview of the breaking feed event. The complete, official release detailing all points, background context, and statements remains hosted by the original publisher.